Anodyne Therapy reimbursement support
This article was originally published in The Gray Sheet
Executive Summary
More than 1,000 patients and physical therapists submitted comments to CMS in support of national coverage for the Anodyne Therapy infrared device to treat peripheral neuropathy during the comment period ended Feb. 26. Anodyne contacted customers to encourage them to voice their support, a strategy that it has successfully used to reverse previous local coverage denials. In the internally generated national coverage request, CMS cites concerns from an FDA warning letter to the manufacturer as an impetus for considering national non-coverage of the device (1"The Gray Sheet" Feb. 6, 2006, p. 5). CMS plans to issue a proposed decision by July 26...
You may also be interested in...
In Rare Move, CMS Cites FDA Warning Letter In National Coverage Request
CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.